LEADER 01252nam--2200397---450 
001 990005796470203316
005 20240213135201.0
010   $a978-0-12-397927-8
035   $a000579647
035   $aUSA01000579647
035   $a(ALEPH)000579647USA01
035   $a000579647
100   $a20130116d2012----km-y0itay50------ba
101 0 $aeng
102   $aUS
105   $a||||||||001yy
200 1 $aCurrent Challenges In Personalized Cancer medicine$fEdited by Keiran S. M. Smalley ; S. J. Enna
210   $aAmsterdam [etc.]$cElsevier$d2012
215   $aXVIII, 558 p.$d24 cm
225 2 $aAdvances in pharmacology$v65
410  0$1001000609420$12001$aAdvances in pharmacology$v65
606   $aFarmacologia$2BNCF
606 0 $aTumori$2BNCF
676   $a616.992075
702  1$aENNA,$bS.J.
801  0$aIT$bsalbc$gISBD
912   $a990005796470203316
951   $a615 AIP/ 65$b5662 Farm$c615$d00313107
959   $aBK
969   $aFAR
979   $aPASSARO$b90$c20130116$lUSA01$h1142
979   $aPASSARO$b90$c20130116$lUSA01$h1144
979   $aPASSARO$b90$c20130116$lUSA01$h1148
979   $aPASSARO$b90$c20130116$lUSA01$h1156
996   $aCurrent Challenges In Personalized Cancer medicine$91080870
997   $aUNISA